ALKS Alkermes plc.
FY2025 10-K
Alkermes plc. (ALKS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Pharmaceutical development and licensing for specialty medicines, with substantial collaboration and royalty revenues from partners Janssen and Biogen
- • Strategic shift: Sale of Athlone manufacturing facility in May 2024 and transition of VUMERITY manufacturing to Biogen's subcontractor completed August 2025
Management Discussion & Analysis
- • Revenue product sales, net $1,184.6M up $101.1M YoY from $1,083.5M, driven by LYBALVI (+$66.7M) and ARISTADA (+$23.8M) growth
- • Manufacturing and royalty revenues declined $182.8M to $291.3M, mainly from long-acting INVEGA products down $126.9M
Risk Factors
- • Regulatory risk: potential increased tax liability of ~$70M on $965.7M in cumulative unremitted U.S. earnings upon repatriation subject to foreign tax credits and withholding
- • Macroeconomic threat: $1.525B senior secured term loans due 2031 with interest margins of 1.75%-2.75% increase financing costs and leverage post-Avadel Acquisition
Financial SummaryXBRL
Revenue
$1.5B
Net Income
$242M
Operating Margin
17.2%
Net Margin
16.4%
ROE
13.3%
Total Assets
$2.5B
EPS (Diluted)
$1.43
Operating Cash Flow
$521M
Source: XBRL data from Alkermes plc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alkermes plc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.